Mylotarg

1

ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS



2

This medicinal product is subject to additional monitoring. This will allow quick identification of new 
safety information. Healthcare professionals are asked to report any suspected adverse reactions. See 
section 4.8 for how to report adverse reactions.

1. NAME OF THE MEDICINAL PRODUCT

MYLOTARG 5 mg powder for concentrate for solution for infusion

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each vial of powder for concentrate for solution for infusion contains 5 mg gemtuzumab ozogamicin.

After reconstitution (see section 6.6), the concentrated solution contains 1 mg/mL gemtuzumab ozogamicin.

Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of the CD33-directed monoclonal 
antibody (hP67.6; recombinant humanised immunoglobulin [Ig] G4, kappa antibody produced by 
mammalian cell culture in NS0 cells) that is covalently linked to the cytotoxic agent 
N-acetyl gamma calicheamicin.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Powder for concentrate for solution for infusion (powder for concentrate).

White to off-white cake or powder.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

MYLOTARG is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the 
treatment of patients age 15 years and above with previously untreated, de novo CD33-positive acute 
myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL) (see sections 4.4 and 5.1).

4.2 Posology and method of administration

MYLOTARG should be administered under the supervision of a physician experienced in the use of 
anticancer medicinal products and in an environment where full resuscitation facilities are immediately 
available.

MYLOTARG should be used only in patients eligible to receive intensive induction chemotherapy.

Premedication with a corticosteroid, antihistamine, and acetaminophen (or paracetamol) is recommended 
1 hour prior to dosing to help ameliorate infusion-related symptoms (see section 4.4).

Appropriate measures to help prevent the development of tumour lysis-related hyperuricaemia, such as 
hydration, administration of antihyperuricemic or other agents for treatment of hyperuricaemia should be 
taken (see section 4.4).



3

Posology

Induction 

The recommended dose of MYLOTARG is 3 mg/m2/dose (up to a maximum of one 5 mg vial) infused over 
a 2-hour period on Days 1, 4, and 7 in combination with DNR 60 mg/m2/day infused over 30 minutes on 
Day 1 to Day 3, and AraC 200 mg/m2/day by continuous infusion on Day 1 to Day 7.

If a second induction is required, MYLOTARG should not be administered during second induction therapy.
Only DNR and AraC should be administered during the second induction cycle, at the following
recommended dosing: DNR 35 mg/m2/day on Days 1 and 2, and AraC 1 g/m2 every 12 hours, on Day 1 to 
Day 3.

Consolidation 

For patients experiencing a complete remission (CR) following induction, defined as fewer than 5% blasts in 
a normocellular marrow and an absolute neutrophil count (ANC) of more than 1.0 × 109 cells/L with a 
platelet count of 100 × 109/L or more in the peripheral blood in the absence of transfusion, up to 2 
consolidation courses of intravenous DNR (60 mg/m2 for 1 day [first course] or 2 days [second course]) in 
combination with intravenous AraC (1 g/m2 per 12 hours, infused over 2 hours on Day 1 to Day 4) with 
intravenous MYLOTARG (3 mg/m2/dose infused over 2 hours up to a maximum dose of one 5 mg vial on 
Day 1) are recommended.

Table 1. Dosing regimens for MYLOTARG in combination with chemotherapy

Treatment 
course

MYLOTARG daunorubicin cytarabine

Inductiona
3 mg/m2/dose (up to a 
maximum of one 5 mg
vial) on Days 1, 4, and 7

60 mg/m2/day on Day 1 to 
Day 3

200 mg/m2/day on Day 1
to Day 7

Second 
induction (if 
required)

MYLOTARG should not 
be administered during 
second induction.

35 mg/m2/day on Day 1 to 
Day 2

1 g/m2/every 12 hours on 
Day 1 to Day 3

Consolidation 
Course 1a,b

3 mg/m2/dose (up to a 
maximum of one 5 mg
vial) on Day 1

60 mg/m2/day on Day 1
1 g/m2/every 12 hours on
Day 1 to Day 4

Consolidation 
Course 2a,b

3 mg/m2/dose (up to a 
maximum of one 5 mg
vial) on Day 1

60 mg/m2/day on Day 1 to 
Day 2

1 g/m2/every 12 hours on 
Day 1 to Day 4

a. See Table 3 and Table 4 for dose modification information.
b. For patients experiencing a complete remission (CR) following induction.



4

Dose and schedule modifications

Schedule modification for hyperleukocytosis

In patients with hyperleukocytic (leukocyte count ≥ 30,000/mm3) AML, cytoreduction is recommended 
either with leukapheresis, oral hydroxyurea or AraC with or without hydroxyurea to reduce the peripheral 
white blood cell (WBC) count 48 hours prior to administration of MYLOTARG. 

If AraC is used for leukoreduction with or without hydroxyurea in patients with previously untreated, 
de novo hyperleukocytic AML receiving MYLOTARG in combination therapy, apply the following 
modified schedule (Table 2):

Table 2. Schedule modification for the treatment of hyperleukocytosis with cytarabine

Treatment 
course

MYLOTARG daunorubicin cytarabine hydroxyurea

Inductiona

3 mg/m2/dose (up to a 
maximum of one 5 mg
vial) on Days 3, 6, and 9

60 mg/m2/day on 
Day 3 to Day 5

200 mg/m2/day on 
Day 1 to Day 7

Day 1 (as per 
standard medical 
practice)

See Table 1 for dose recommendations for consolidation course.
a. See Table 3 and Table 4 for additional dose modification information.

Dose modification for adverse reactions

Dose modification of MYLOTARG is recommended based on individual safety and tolerability (see 
section 4.4). Management of some adverse reactions may require dose interruptions or permanent 
discontinuation of MYLOTARG (see sections 4.4 and 4.8).

Tables 3 and 4 show the dose modification guidelines for haematological and non-haematological toxicities, 
respectively.

Table 3. Dose modifications for haematological toxicities
Haematological toxicities Dose modifications
Persistent thrombocytopenia
(Platelets < 100,000/mm3 at the 
planned start date of the 
consolidation course)

 Postpone start of consolidation course. 

 If platelet count recovers to ≥ 100,000/mm3 within 14 days 
following the planned start date of the consolidation course: 
initiate consolidation therapy (see as described in Table 1).

 If platelet count recovers to < 100,000/mm3 and 
≥ 50,000/mm3 within 14 days following the planned start 
date of the consolidation course: MYLOTARG should not 
be re-introduced and consolidation therapy should consist of 
DNR and AraC only.

 If platelet count recovery remains < 50,000/mm3 for greater 
than 14 days consolidation therapy should be re-evaluated 
and a BMA should be performed to re-assess the patients’ 
status.



5

Persistent neutropenia  If neutrophil count does not recover to greater than 500/mm3

within 14 days following the planned start date of the 
consolidation cycle (14 days after haematologic recovery 
following previous cycle), discontinue MYLOTARG (do not 
administer MYLOTARG in the consolidation cycles).

Abbreviations: AML=acute myeloid leukaemia; AraC=cytarabine; BMA=bone marrow aspirate, 
DNR=daunorubicin.

Table 4. Dose modifications for non-haematological toxicities
Non-haematological toxicities Dose modifications
VOD/SOS Discontinue MYLOTARG (see section 4.4).
Total bilirubin > 2 × ULN and 
AST and/or ALT > 2.5 × ULN 

Postpone MYLOTARG until recovery of total bilirubin to ≤ 2 × ULN 
and AST and ALT to ≤ 2.5 × ULN prior to each dose.
Consider omitting scheduled dose if delayed more than 2 days 
between sequential infusions.

Infusion related reactions Interrupt the infusion and institute appropriate medical management 
based on the severity of symptoms. Patients should be monitored until 
signs and symptoms completely resolve and infusion may resume. 
Consider permanent discontinuation of treatment for severe or 
life-threatening infusion reactions (see section 4.4).

Other severe or life-threatening 
non-haematologic toxicities

Delay treatment with MYLOTARG until recovery to a severity of no 
more than mild.  
Consider omitting scheduled dose if delayed more than 2 days 
between sequential infusions.

Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; SOS=sinusoidal obstruction
syndrome; ULN=upper limit of normal; VOD=venoocclusive disease.

Special populations

Use in patients with hepatic impairment

No adjustment of the starting dose is required in patients with hepatic impairment defined by total bilirubin 
≤ 2 × upper limit of normal (ULN) and aspartate aminotransferase (AST)/alanine aminotransferase (ALT) 
≤ 2.5 × ULN. Postpone MYLOTARG until recovery of total bilirubin to ≤ 2 × ULN and AST and ALT to 
≤ 2.5 × ULN prior to each dose (see Table 4, sections 4.4 and 5.2). 

Use in patients with renal impairment

No dose adjustment is required in patients with mild to moderate renal impairment. MYLOTARG has not 
been studied in patients with severe renal impairment. MYLOTARG does not undergo renal clearance, the 
pharmacokinetics in patients with severe renal impairment is unknown (see section 5.2).

Elderly patients

No dose adjustment is required in elderly patients (≥ 65 years) (see section 5.2).

Paediatric population

The safety and efficacy of MYLOTARG in patients less than 15 years of age has not been established. 
Currently available data are described in sections 4.8, 5.1, and 5.2 but no recommendation on a posology can 
be made.

Method of administration

MYLOTARG is for intravenous use and must be reconstituted and diluted before administration (see 
section 6.6). When reconstituted to a 1 mg/mL concentration, the extractable content of one vial is 4.5 mg 
(4.5 mL). The reconstituted and diluted solution should be administered intravenously by infusion over a 



6

2-hour period under close clinical monitoring, including pulse, blood pressure, and temperature. 
MYLOTARG should not be administered as an intravenous push or bolus (see section 6.6).

For instructions on reconstitution and dilution of the medicinal product before administration, see 
section 6.6.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the 
administered product should be clearly recorded.

Hepatotoxicity, including hepatic venoocclusive disease/sinusoidal obstruction syndrome (VOD/SOS)

Hepatotoxicity, including life-threatening, and sometimes fatal hepatic failure and VOD/SOS have been 
reported in patients treated with MYLOTARG (see section 4.8).

Based on an analysis of potential risk factors, adult patients who received MYLOTARG as monotherapy, 
either before or after an haematopoietic stem cell transplant (HSCT), and patients with moderate or severe 
hepatic impairment are at increased risk for developing VOD (see section 4.8).

Due to the risk of VOD/SOS, signs and symptoms of VOD/SOS should be closely monitored; these may 
include elevations in ALT, AST, total bilirubin, and alkaline phosphatase, which should be monitored prior 
to each dose of MYLOTARG, hepatomegaly (which may be painful), rapid weight gain, and ascites. 
Monitoring only total bilirubin may not identify all patients at risk of VOD/SOS. For patients who develop 
abnormal liver tests, more frequent monitoring of liver tests and clinical signs and symptoms of 
hepatotoxicity is recommended. For patients who proceed to HSCT, close monitoring of liver tests is 
recommended during the post-HSCT period, as appropriate. No definitive relationship was found between 
VOD and time of HSCT relative to higher MYLOTARG monotherapy doses, however, the ALFA-0701 
study recommended an interval of 2 months between the last dose of MYLOTARG and HSCT.

Management of signs or symptoms of hepatic toxicity may require a dose interruption, or discontinuation of 
MYLOTARG (see section 4.2). In patients who experience VOD/SOS, MYLOTARG should be 
discontinued and patients treated according to standard medical practice.

Infusion related reactions (including anaphylaxis)

In clinical studies infusion related reactions, including anaphylaxis were reported (see section 4.8). There 
have been reports of fatal infusion reactions in the post-marketing setting. Signs and symptoms of infusion 
related reactions may include fever and chills, and less frequently hypotension, tachycardia, and respiratory 
symptoms that may occur during the first 24 hours after administration. Infusion of MYLOTARG should be 
performed under close clinical monitoring, including pulse, blood pressure, and temperature. Premedication 
with a corticosteroid, antihistamine and acetaminophen (or paracetamol) is recommended 1 hour prior to 
MYLOTARG dosing (see section 4.2). Infusion should be interrupted immediately for patients who develop 
evidence of severe reactions, especially dyspnoea, bronchospasm, or clinically significant hypotension. 
Patients should be monitored until signs and symptoms completely resolve. Discontinuation of treatment 
should be strongly considered for patients who develop signs or symptoms of anaphylaxis, including severe 
respiratory symptoms or clinically significant hypotension (see section 4.2).



7

Myelosuppression

In clinical studies, neutropenia, thrombocytopenia, anaemia, leukopenia, febrile neutropenia, lymphopenia, 
and pancytopenia, some of which were life-threatening or fatal, were reported (see section 4.8).
Complications associated with neutropenia and thrombocytopenia may include infections and 
bleeding/haemorrhagic reactions respectively. Infections and bleeding/haemorrhagic reactions were reported, 
some of which were life-threatening or fatal.

Complete blood counts should be monitored prior to each dose of MYLOTARG. During treatment, patients 
should be monitored for signs and symptoms of infection, bleeding/haemorrhage, or other effects of 
myelosuppression. Routine clinical and laboratory surveillance testing during and after treatment is 
indicated.

Management of patients with severe infection, bleeding/haemorrhage, or other effects of myelosuppression, 
including severe neutropenia or persistent thrombocytopenia, may require a dose delay or permanent 
discontinuation of MYLOTARG (see section 4.2).

Tumour lysis syndrome (TLS)

In clinical studies, TLS was reported (see section 4.8). Fatal reports of TLS complicated by acute renal 
failure have been reported in the post-marketing setting. In patients with hyperleukocytic AML, 
leukoreduction should be considered with hydroxyurea or leukapheresis to reduce the peripheral WBC count 
to below 30,000/mm3 prior to administration of MYLOTARG to reduce the risk of inducing TLS (see 
section 4.2).

Patients should be monitored for signs and symptoms of TLS and treated according to standard medical 
practice. Appropriate measures to help prevent the development of tumour lysis-related hyperuricaemia, such 
as hydration, administration of antihyperuricemics (e.g., allopurinol) or other agents for treatment of 
hyperuricaemia (e.g., rasburicase) must be taken.

AML with adverse-risk cytogenetics

The efficacy of MYLOTARG has been shown in AML patients with favourable- and intermediate-risk 
cytogenetics, with uncertainty regarding the size of the effect in patients with adverse cytogenetics (see 
section 5.1). For patients being treated with MYLOTARG in combination with daunorubicin and cytarabine 
for newly diagnosed de novo AML, when cytogenetics testing results become available it should be 
considered whether the potential benefit of continuing treatment with MYLOTARG outweighs the risks for 
the individual patient (see section 5.1).

Contraception

Women of childbearing potential, or partners of females of childbearing potential should be advised to use 
2 methods of effective contraception during treatment with MYLOTARG for at least 7 months (females) or 
4 months (males) after the last dose (see section 4.6).

Excipients

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 
‘sodium-free’.

This medicinal product may be further prepared for administration with sodium-containing solutions (see 
sections 4.2 and 6.6) and this should be considered in relation to the total sodium from all sources that will 
be administered to the patient.



8

4.5 Interaction with other medicinal products and other forms of interaction

No clinical drug interaction studies have been conducted with MYLOTARG. See section 5.2 for available 
data from in vitro studies.

4.6 Fertility, pregnancy and lactation

Women of childbearing potential/Contraception in males and females

Women of childbearing potential should be advised to avoid becoming pregnant while receiving 
MYLOTARG.

Women of childbearing potential, or partners of females of childbearing potential should be advised to use 
2 methods of effective contraception during treatment with MYLOTARG for at least 7 months (females) or 
4 months (males) after the last dose.

Pregnancy

There are no or limited amount of data from the use of gemtuzumab ozogamicin in pregnant women. Studies 
in animals have shown reproductive toxicity (see section 5.3).

MYLOTARG must not be used during pregnancy unless the potential benefit to the mother outweighs the 
potential risks to the foetus. Pregnant women, or patients becoming pregnant whilst receiving gemtuzumab 
ozogamicin, or treated male patients as partners of pregnant women, must be apprised of the potential hazard 
to the foetus.

Breast-feeding

There is no information regarding the presence of gemtuzumab ozogamicin or its metabolites in human milk, 
the effects on the breast-fed child, or the effects on milk production. Because of the potential for adverse 
reactions in breast-fed children, women should not breast-feed during treatment with MYLOTARG and for 
at least 1 month after the final dose (see section 5.3).

Fertility

There is no information on fertility in patients. Based on non-clinical findings, male and female fertility may 
be compromised by treatment with gemtuzumab ozogamicin (see section 5.3). Both men and women should 
seek advice on fertility preservation before treatment.

4.7 Effects on ability to drive and use machines

MYLOTARG has moderate influence on the ability to drive and use machines. Patients should be advised 
they may experience fatigue, dizziness and headache during treatment with MYLOTARG (see section 4.8). 
Therefore, caution should be exercised when driving or operating machines.

4.8 Undesirable effects

Summary of the safety profile

The overall safety profile of MYLOTARG is based on data from patients with acute myeloid leukaemia from 
the combination therapy study ALFA-0701, monotherapy studies, and from post-marketing experience. In 
the combination therapy study, safety data consisting of selected treatment emergent adverse events (TEAEs) 
considered most important for understanding the safety profile of MYLOTARG consisted of all grades 
haemorrhages, all grades VOD, and severe infections. All of these TEAEs were determined to be adverse 
drug reactions. Because of this limited data collection, laboratory data from the combination therapy study
are included in Table 5. Information about adverse drug reactions from monotherapy studies and 
post-marketing experience is presented Table 6 in order to provide full characterisation of adverse reactions.



9

In the combination therapy study ALFA-0701, clinically relevant serious adverse reactions were 
hepatotoxicity, including VOD/SOS (3.8%), haemorrhage (9.9%), severe infection (41.2%), and tumour lysis 
syndrome (1.5%). In monotherapy studies, clinically relevant serious adverse reactions also included 
infusion related reactions (2.5%), thrombocytopenia (21.7%), and neutropenia (34.3%). 

The most common adverse reactions (> 30%) in the combination therapy study were haemorrhage and 
infection. In monotherapy studies the most common adverse reactions (> 30%) included pyrexia, nausea, 
infection, chills, haemorrhage, vomiting, thrombocytopenia, fatigue, headache, stomatitis, diarrhoea, 
abdominal pain, and neutropenia.

The most frequent (≥ 1%) adverse reactions that led to permanent discontinuation in the combination therapy 
study were thrombocytopenia, VOD, haemorrhage and infection. The most frequent (≥ 1%) adverse reactions 
that led to permanent discontinuation in monotherapy studies were infection, haemorrhage, multi-organ 
failure, and VOD.

Tabulated list of adverse reactions

The adverse reactions are presented by system organ class (SOC) and frequency categories, defined using the 
following convention: very common ( 1/10), common ( 1/100 to < 1/10), uncommon ( 1/1,000 to 
< 1/100), rare ( 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the 
available data). Within each frequency grouping, adverse reactions are presented in order of decreasing 
seriousness.



10

Table 5. Selected** adverse reactions in patients who received MYLOTARG in combination 
therapy study (ALFA-0701)

System organ class
Frequency

Preferred term

MYLOTARG + daunorubicin 
+ cytarabine (N=131)

daunorubicin 
+ cytarabine (N=137)

All grades
%

Grade 3/4
%

All grades
%

Grade 3/4
%

Infections and infestations
Very common

Infection*a 77.9 76.3 77.4 74.4
Vascular disorders
Very common

Haemorrhage*b 90.1 20.6 78.1 8.8
Hepatobiliary disorders
Common

Venoocclusive liver disease*c 4.6 2.3 1.5 1.5
Investigations ***
Very common

Haemoglobin decreased 100 86.2 100 89.7
Platelets decreased 100 100 100 100
White blood cells decreased 100 100 99.3 99.3
Lymphocytes (absolute) 
decreased

98.5 90.7 97.8 89.6

Neutrophils decreased 97.7 96.1 98.5 97.0
Hyperglycaemia 92.0 19.2 91.1 17.8
Aspartate aminotransferase 
(AST) increased

89.2 14.0 73.9 9.0

Prothrombin time increased 84.8 3.3 89.1 0
Activated partial 
thromboplastin time prolonged

80.0 6.4 57.5 5.5

Alkaline phosphatase 
increased

79.7 13.3 68.9 5.3

Alanine aminotransferase 
(ALT) increased

78.3 10.9 81.3 15.7

Blood bilirubin increased 51.6 7.1 50.8 3.8
Hyperuricaemia 32.5 2.6 28.5 0

Abbreviations: N=number of patients; PT=preferred term.
*Including fatal outcome.
**Only selected safety data were collected in this study of newly diagnosed AML. 
***Frequency is based on laboratory values (Grade per NCI CTCAE v4.03).
a. Infection includes Sepsis and Bacteraemia (53.4%), Fungal infection (15.3%), Lower respiratory tract infection 

(5.3%), Bacterial infection (9.2%), Gastrointestinal infection (8.4%), Skin infection (2.3%), and Other infections 
(28.4%).

b. Haemorrhage includes Central nervous system haemorrhage (3.1%), Upper gastrointestinal haemorrhage (33.6%), 
Lower gastrointestinal haemorrhage (17.6%), Subcutaneous haemorrhage (60.3%), Other haemorrhage (64.9%), and 
Epistaxis (62.6%).

c. Venoocclusive liver disease includes the following reported PTs: Venoocclusive disease and Venoocclusive liver 
disease*.



11

Table 6. Adverse reactions in patients who received MYLOTARG in monotherapy*** studies and 
post-marketing

System organ class
  Frequency

Preferred term

All grades
%

Grade 3/4
%

Infections and infestations
  Very common

Infection*a 68.2 32.8
Blood and lymphatic system disorders
  Very common

Febrile neutropenia 19.1 11.6
Thrombocytopeniab 48.4 48.0
Neutropeniac 30.3 29.2
Anaemiad 27.1 24.2
Leukopeniae 26.7 26.7

  Common
Pancytopeniaf 5.0 4.3
Lymphopeniag 3.6 3.2

Immune system disorders
  Common

Infusion related reactionh 7.6 3.6
Metabolism and nutrition disorders
  Very common

Hyperglycaemiai 11.2 6.9

Decreased appetite 27.1 6.1
  Common

Tumour lysis syndrome** 2.5 1.8
Nervous system disorders
  Very common

Headache 38.3 12.3
Cardiac disorders
  Very common

Tachycardiaj 13.0 4.3
Vascular disorders
  Very common

Haemorrhage*k 67.1 23.8
Hypotensionl 20.2 14.8
Hypertensionm 17.3 10.5

Respiratory, thoracic and mediastinal 
disorders
  Very common

Dyspnoean 27.4 12.6
  Unknown

Interstitial pneumonia*

Gastrointestinal disorders
  Very common

Vomiting 60.6 33.6
Diarrhoea 33.9 14.8
Abdominal paino 33.2 7.2
Nausea 71.1 39.3
Stomatitisp 36.1 12.3
Constipation 25.3 5.0

Common
Ascites 2.9 0.4
Dyspepsia 8.7 1.1
Oesophagitis 1.8 0.7

  Unknown
Neutropenic colitis*



12

Hepatobiliary disorders
  Very common

Transaminases increasedq 24.5 18.8
Hyperbilirubinaemiar 13.0 10.5

  Common
Venoocclusive liver disease*s 2.9 1.1
Hepatomegaly 2.5 0.7
Jaundice 2.2 1.1
Hepatic function abnormalt 2.5 1.4
Gamma-glutamyltransferase increased 1.8 0.7

  Uncommon
Hepatic failure*# 0.4 0.4
Budd-Chiari syndrome# 0.4 0.4

Skin and subcutaneous tissue disorders
  Very common

Rashu 19.9 5.8
  Common

Erythemav 9.4 2.2
Pruritus 5.4 0.4

Renal and urinary disorders
  Unknown

Haemorrhagic cystitis*

General disorders and administration 
site conditions
  Very common

Pyrexiaw 82.7 52.3
Oedemax 21.3 3.2
Fatiguey 41.2 11.2
Chills 67.9 17.3

  Common
Multi-organ failure* 2.2 0.7

Investigations
  Very common

Blood lactate dehydrogenase increased 16.6 7.2
  Common

Blood alkaline phosphate increased 8.7 6.1
*Including fatal outcome.
**Including fatal adverse reactions in the post-marketing setting.
***MYLOTARG in the treatment of relapsed AML (9 mg/m2). 
#Singular cases.
Abbreviation: PT=preferred term.
a. Infection includes Sepsis and Bacteraemia (25.6%), Fungal infection (10.5%), Lower respiratory tract infection 

(13.0%), Upper respiratory tract infection (4.3%), Bacterial infection (3.6%), Viral infection (24.2%), Gastrointestinal 
infection (3.3%), Skin infection (7.9%), and Other infections (19.5%). Post-marketing (frequency category unknown) 
fungal lung infections including Pulmonary mycosis and Pneumocystis jirovecii pneumonia*; and bacterial infections 
including Stenotrophomonas infection were also reported.

b. Thrombocytopenia includes the following reported PTs: Platelet count decreased and Thrombocytopenia*.
c. Neutropenia includes the following reported PTs: Neutropenia, Granulocytopenia and Neutrophil count decreased.
d. Anaemia includes the following reported PTs: Anaemia and Haemoglobin decreased.
e. Leukopenia includes the following reported PTs: Leukopenia and White blood cell count decreased.
f. Pancytopenia includes the following reported PTs: Pancytopenia and Bone marrow failure.
g. Lymphopenia includes the following reported PTs: Lymphopenia and Lymphocyte count decreased.
h. Infusion related reaction includes the following reported PTs: Infusion related reaction, Urticaria, Hypersensitivity, 

Bronchospasm, Drug hypersensitivity, and Injection site urticaria#.
i. Hyperglycaemia includes the following reported PTs: Hyperglycaemia and Blood glucose increased#.
j. Tachycardia includes the following reported PTs: Tachycardia, Sinus tachycardia, Heart rate increased#, and 

Supraventricular tachycardia#.
k. Haemorrhages include Central nervous system haemorrhage (5.1%), Upper gastrointestinal haemorrhage (21.3%), 

Lower gastrointestinal haemorrhage (15.2%), Subcutaneous haemorrhage (28.5%), Other haemorrhage (32.9%), and 
Epistaxis (28.5%). 

l. Hypotension includes the following reported PTs: Hypotension and Blood pressure decreased.
m. Hypertension includes the following reported PTs: Hypertension and Blood pressure increased.
n. Dyspnoea includes the following reported PTs: Dyspnoea and Dyspnoea exertional.
o. Abdominal pain includes the following reported PTs: Abdominal pain, Abdominal pain lower, Abdominal pain 

upper, Abdominal discomfort, and Abdominal tenderness.



13

p. Stomatitis includes the following reported PTs: Mucosal inflammation, Oropharyngeal pain, Stomatitis, Mouth 
ulceration, Oral pain, Oral mucosal blistering, Aphthous stomatitis, Tongue ulceration, Glossodynia, Oral mucosal 
erythema, Glossitis#, and Oropharyngeal blistering#.

q. Transaminases increased includes the following reported PTs: Transaminases increased, Hepatocellular injury, 
Alanine aminotransferase increased, Aspartate aminotransferase increased, and Hepatic enzyme increased.

r. Hyperbilirubinaemia includes the following reported PTs: Blood bilirubin increased and Hyperbilirubinaemia.
s. Venoocclusive liver disease includes the following reported PTs: Venoocclusive disease and Venoocclusive liver 

disease*#.
t. Hepatic function abnormal includes the following reported PTs: Liver function test abnormal and Hepatic function 

abnormal.
u. Rash includes the following reported PTs: Rash, Dermatitis#, Dermatitis allergic#, Dermatitis bullous, Dermatitis 

contact, Dermatitis exfoliative#, Drug eruption, Pruritus allergic# and Rash erythematous#, Rash macular#, Rash 
maculo papular, Rash papular, Rash pruritic, Rash vesicular#.

v. Erythema includes the following reported PTs: Catheter site erythema, Erythema and Infusion site erythema#.
w. Pyrexia includes the following reported PTs: Pyrexia, Body temperature increased, and Hyperthermia.
x. Oedema includes the following reported PTs: Oedema, Face oedema, Oedema peripheral, Swelling face, Generalised 

oedema, and Periorbital oedema.
y. Fatigue includes the following reported PTs: Fatigue, Asthenia, Lethargy, and Malaise.

Description of selected adverse reactions

Hepatotoxicity, including hepatic VOD/SOS

In the combination therapy study, VOD and hepatic laboratory abnormalities were collected. Additional
characterisation of hepatotoxicity adverse reactions is provided from the monotherapy studies.

In the combination therapy study (N=131), VOD was reported in 6 (4.6%) patients during or following 
treatment, 2 (1.5%) of these reactions were fatal (see Table 5). Five (3.8%) of these VOD reactions occurred 
within 28 days of any dose of gemtuzumab ozogamicin. One VOD event occurred more than 28 days of last 
dose of gemtuzumab ozogamicin; with 1 of these events occurring a few days after having started an HSCT 
conditioning regimen. The median time from the last gemtuzumab ozogamicin dose to onset of VOD was 
9 days (range: 2-298 days). VOD was also reported in 2 patients who received MYLOTARG as a follow-up 
therapy following relapse of AML after chemotherapy treatment in the control arm of the combination 
therapy study. Both of these patients experienced VOD more than 28 days after the last dose of gemtuzumab 
ozogamicin. One of these patients experienced VOD 25 days after the subsequent HSCT.

Based on an analysis of potential risk factors, adult patients who received MYLOTARG as monotherapy, 
patients who had received an HSCT prior to gemtuzumab ozogamicin exposure were 2.6 times more likely 
(95% CI: 1.448, 4.769) to develop VOD compared to patients without HSCT prior to treatment with 
gemtuzumab ozogamicin; patients who had received an HSCT following treatment with gemtuzumab 
ozogamicin were 2.9 times more likely (95% CI: 1.502, 5.636) to develop VOD compared to patients 
without HSCT following treatment with gemtuzumab ozogamicin; and patients who had moderate/severe 
hepatic impairment at baseline were 8.7 times more likely (95% CI: 1.879, 39.862) to develop VOD 
compared to patients without moderate/severe hepatic impairment at baseline.

Patients should be monitored for hepatotoxicity as recommended in section 4.4. Management of signs or 
symptoms of hepatic toxicity may require a dose interruption, or discontinuation of MYLOTARG (see 
section 4.2).

Myelosuppression

In the combination therapy study in patients with previously untreated de novo AML treated with 
fractionated doses of gemtuzumab ozogamicin in combination with chemotherapy, Grade 3/4 decreases in 
leukocytes, neutrophils, and platelets were observed in 131 (100%), 124 (96.1%), and 131 (100%) patients, 
respectively.

During the induction phase, 109 (83.2%) and 99 (75.6%) patients had platelet recovery to counts of 
50,000/mm3 and 100,000/mm3, respectively. The median times to platelet recovery to counts of 50,000/mm3

and 100,000/mm3 were 34 and 35 days, respectively. During the consolidation 1 phase, 92 (94.8%) and 
71 (73.2%) patients had a platelet recovery to counts of 50,000/mm3 and 100,000/mm3, respectively. The 



14

median times to platelet recovery to counts of 50,000/mm3 and 100,000/mm3 were 32 and 35 days, 
respectively. During the consolidation 2 phase, 80 (97.6%) and 70 (85.4%) patients had a platelet recovery to 
counts of 50,000/mm3 and 100,000/mm3, respectively. The median times to platelet recovery to counts of 
50,000/mm3 and 100,000/mm3 were 36.5 and 43 days, respectively.

Thrombocytopenia with platelet counts < 50,000/mm3 persisting 45 days after the start of therapy for 
responding patients (CR and incomplete platelet recovery [CRp]) occurred in 22 (20.4%) of patients. The 
number of patients with persistent thrombocytopenia remained similar across treatment courses 
(8 [7.4%] patients at the induction phase and 8 [8.5%] patients at the consolidation 1 phase and 
10 [13.2%] patients at the consolidation 2 phase).

During the induction phase, 121 (92.4%) and 118 (90.1%) patients had a documented neutrophil recovery to 
ANC of 500/mm3 and 1,000/mm3, respectively. The median time to neutrophil recovery to ANC of 500/mm3

and 1,000/mm3 was 25 days. In the consolidation 1 phase of therapy, 94 (96.9%) patients had neutrophil 
recovery to counts of 500/mm3, and 91 (94%) patients recovered to counts of 1,000/mm3. The median times 
to neutrophil recovery to ANC of 500/mm3 and 1,000/mm3 were 21 and 25 days, respectively. In the 
consolidation 2 phase of therapy, 80 (97.6%) patients had neutrophil recovery to counts of 500/mm3, and 
79 (96.3%) patients recovered to counts of 1,000/mm3. The median times to neutrophil recovery to ANC of 
500/mm3 and 1,000/mm3 were 22 and 27 days, respectively.

In the combination therapy study, in patients with de novo AML treated with fractionated doses of 
gemtuzumab ozogamicin in combination with chemotherapy (N=131), 102 (77.9%) patients experienced all 
causality severe (Grade ≥ 3) infections. Treatment-related death due to septic shock was reported in 
1 (0.8%) patients. Fatal severe infection was reported in 2 (1.53%) patients in the MYLOTARG arm and 
4 (2.92%) patients in the control arm.

In the combination therapy study (N=131), all grades and Grade 3/4 bleeding/haemorrhagic reactions were 
reported in 118 (90.1%) and 27 (20.6%) patients, respectively. The most frequent Grade 3 
bleeding/haemorrhagic reactions were haematemesis (3.1%), haemoptysis (3.1%), and haematuria (2.3%). 
Grade 4 bleeding/haemorrhagic reactions were reported in 4 (3.1%) patients (gastrointestinal haemorrhage, 
haemorrhage, and pulmonary alveolar haemorrhage [2 patients]). Fatal bleeding/haemorrhagic reactions
were reported in 3 (2.3%) patients (cerebral haematoma, intracranial haematoma, and subdural haematoma).

Management of patients with severe infection, bleeding/haemorrhage, or other effects of myelosuppression, 
including severe neutropenia or persistent thrombocytopenia, may require a dose delay or permanent 
discontinuation of MYLOTARG (see sections 4.2 and 4.4).

Immunogenicity

As with all therapeutic proteins, there is potential for immunogenicity. 

In clinical studies of MYLOTARG in patients with relapsed or refractory AML, the immunogenicity of 
MYLOTARG was evaluated using 2 enzyme-linked immunosorbent assays (ELISAs).

Patients in the Phase 2 trials did not develop antidrug antibodies (ADAs) and only 2 patients in a Phase 1 
trial developed antibodies against the calicheamicin-linker complex, 1 of whom had reduced hP67.6 plasma 
concentrations. Overall, the incidence rate of ADA development after MYLOTARG treatment was < 1% 
across the 4 clinical studies with ADA data. Definitive conclusions cannot be drawn between the presence of 
antibodies and potential impact on efficacy and safety due to the limited number of patients with positive 
ADAs.

The detection of ADAs is highly dependent on the sensitivity and specificity of the assay. The incidence of 
antibody positivity in an assay may be influenced by several factors, including assay methodology, 
circulating gemtuzumab ozogamicin concentrations, sample handling, timing of sample collection, 
concomitant treatments and underlying disease. For these reasons, comparison of incidence of antibodies to 
gemtuzumab ozogamicin with the incidence of antibodies to other products may be misleading.



15

Paediatric population

Previously untreated AML

The safety and efficacy of MYLOTARG in children and adolescents with previously untreated AML below 
the age of 15 years has not been established (see section 4.2).

In the completed randomised paediatric Phase 3 Study AAML0531 (see section 5.1) of gemtuzumab 
ozogamicin combined with intensive first-line therapy in 1,063 newly diagnosed children (93.7% of patients 
<18 years of age), and young adults (6.3% of patients) with de novo AML aged 0 to 29 years, the safety 
profile was similar with that observed in the other studies of gemtuzumab ozogamicin combined with 
intensive chemotherapy in adult patients with de novo AML. However, the optimal dose of gemtuzumab 
ozogamicin for paediatric patients was not established, since in Study AAML0531 during the second 
intensification period after the second dose of gemtuzumab ozogamicin, a larger proportion of patients in the 
gemtuzumab ozogamicin arm experienced prolonged neutrophil recovery time (> 59 days) as compared with 
the comparator arm (21.0% versus 11.5%), and more patients died during remission (5.5% versus 2.8%).

Relapsed or refractory AML

The safety and efficacy of MYLOTARG in paediatric patients with relapsed or refractory AML has not been 
established (see sections 4.1 and 4.2).

Safety results observed in a systematic literature review of studies evaluating MYLOTARG in paediatric 
patients (see section 5.1), are presented in Table 7.

Table 7. Safety results from a systematic literature review in paediatric patients with relapsed or 
refractory AML who received MYLOTARG

Monotherapy Combinationa

Fractionatedb 

MYLOTARG
Non-fractionatedb

MYLOTARG
Fractionatedb 

MYLOTARG
Non-fractionatedb 

MYLOTARG
Number 
of 
studies

N per 
study 
(range)

Ratec 

(%)
Number 
of 
studies

N per 
study 
(range)

Rate 
(%)

Number 
of 
studies

N per 
study 
(range)

Rate 
(%)

Number 
of 
studies

N per 
study 
(range)

Rate 
(%)

VOD 1 6 0 10 5, 30 6.8 2 3, 17 0 5 5, 84 4.4 
VOD post HSCT Not reported 5 4, 14 19.1 2 3, 8 0 2 12, 28 14.7
Deathd 1 6 0 4 6, 29 10.8 Not reported 3 5, 45 6.5
Infection 5 studies; N per study (range) 12-30; 28.4% 4 studies; N per study (range) 12-84; 42.2% 
Myelosuppression
e

Almost all patients (>90 %) experienced myelosuppression across studies

a:  When MYLOTARG was given in combination, cytarabine was part of the combination studied in 8 out of the 9 studies.
b:  Fractionated dosing refers to MYLOTARG dose of 3 mg/m2 on days 1, 4, 7. Non-fractionated dosing refers to MYLOTARG (total dose 

ranging 1.8 mg/m2 – 9 mg/m2) 2 times during a cycle at least 14 days apart.
c:  Rates across studies were estimated using inverse variance weighting with fixed effects. Proportions were transformed using Freeman-Tukey 

double arcsine transformation prior to combining studies, and the estimated combined rate was back-transformed using the harmonic mean 
of study sample sizes.

d:  Within 30 days from the last dose of MYLOTARG.
e:  Where analysed, median recovery (defined as 20 x 109/L or 50 x 109/L for platelets and 0.5 x 109/L for neutrophils) ranged from 42-48 days 

for platelets and 30-37 days for neutrophils.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows 
continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked 
to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

No cases of overdose with MYLOTARG were reported in clinical experience. Single doses higher than 
9 mg/m2 in adults were not tested. Treatment of MYLOTARG overdose should consist of general supportive 
measures.



16

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antineoplastic agents, monoclonal antibodies, ATC code: L01XC05

Mechanism of action

Gemtuzumab ozogamicin is a CD33-directed ADC. Gemtuzumab is a humanised immunoglobulin class G 
subtype 4 (IgG4) antibody which specifically recognises human CD33. The antibody portion binds 
specifically to the CD33 antigen, a sialic acid-dependent adhesion protein found on the surface of myeloid 
leukaemic blasts and immature normal cells of myelomonocytic lineage, but not on normal haematopoietic 
stem cells. The small molecule, N-acetyl gamma calicheamicin, is a cytotoxic semisynthetic natural product. 
N-acetyl gamma calicheamicin is covalently attached to the antibody via an AcBut (4-(4-acetylphenoxy) 
butanoic acid) linker. Non-clinical data suggest that the anticancer activity of gemtuzumab ozogamicin is due 
to the binding of the ADC to CD33-expressing cancer cells, followed by internalisation of the ADC-CD33 
complex, and the intracellular release of N-acetyl gamma calicheamicin dimethyl hydrazide via hydrolytic 
cleavage of the linker. Activation of N-acetyl gamma calicheamicin dimethyl hydrazide induces 
double-stranded DNA breaks, subsequently inducing cell cycle arrest and apoptotic cell death. 

Saturation of a high percentage of CD33 antigenic sites is presumed to be required for maximum delivery of 
calicheamicin to leukaemic blast cells. Several single agent studies measured CD33 saturation 
post-MYLOTARG dose in patients with relapsed and refractory AML. Across all studies, near maximal 
peripheral CD33 saturation was observed post-MYLOTARG dose at all dose levels of 2 mg/m² and above, 
suggesting that a low dose of gemtuzumab ozogamicin is sufficient to bind all available CD33 sites.

Clinical efficacy and safety

ALFA-0701 study of previously untreated patients with de novo AML

The efficacy and safety of MYLOTARG were evaluated in a multicentre, randomised, open-label Phase 3 
study comparing the addition of MYLOTARG to a standard chemotherapy induction regimen of 
daunorubicin and cytarabine (DA) versus DA alone. Eligible patients were between 50 and 70 years of age 
with previously untreated de novo AML (Study ALFA-0701). Patients with acute promyelocytic leukaemia 
(APL, AML3) and patients with AML arising from myelodysplastic syndrome (MDS) or secondary AML
were excluded from the study.

The primary endpoint was event-free survival (EFS). The secondary endpoints included CR and CRp rates, 
relapse-free survival (RFS), overall survival (OS), and safety of the combination DA with or without 
MYLOTARG.

In total, 271 patients were randomised in this study with 135 to induction treatment of 3+7 DA plus 
fractionated 3 mg/m2 × 3 doses of MYLOTARG and 136 to 3+7 DA alone (see section 4.2). A second course 
of induction therapy with DA but without MYLOTARG, regardless of the randomisation arm, was allowed. 
Patients in either arm who did not receive the second course of induction therapy and did not achieve a CR 
after induction could receive a salvage course comprised of idarubicin, AraC, and granulocyte colony-
stimulating factor (G-CSF).

Patients with CR or CRp received consolidation therapy with 2 courses of treatment including DNR and 
AraC with or without MYLOTARG according to their initial randomisation. Patients who experienced 
remission were also eligible for allogeneic transplantation. An interval of at least 2 months between the last 
dose of MYLOTARG and transplantation was recommended.



17

Overall, the median age of patients was 62 years (range 50 to 70 years) and most patients (87.8%) had an 
Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1 at baseline. Baseline 
characteristics were balanced between treatment arms with the exception of gender as a higher percentage of 
males were enrolled in the MYLOTARG arm (54.8%) than in the DA alone arm (44.1%). Overall, 59.0% 
and 65.3% of patients had documented favourable/intermediate-risk disease by the National Comprehensive 
Cancer Network (NCCN) and European LeukaemiaNet (ELN) 2010 risk classifications, respectively. CD33 
expression on AML blasts by flow cytometry harmonised from local laboratory results was determined in 
194/271 (71.6%) patients overall. Few patients (13.7%) had low CD33 expression (less than 30% of blasts).

The trial met its primary objective of demonstrating that MYLOTARG added in fractionated doses 
(3 mg/m2 × 3) to standard induction chemotherapy for patients with previously untreated de novo AML 
resulted in a statistically significant and clinically meaningful improvement in EFS. Median EFS was 
17.3 months (95% CI: 13.4, 30.0) in the MYLOTARG arm versus 9.5 months (95% CI: 8.1, 12.0) in the DA 
alone arm; hazard ratio (HR) 0.562 (95% CI: 0.415, 0.762); 2-sided p=0.0002 by log-rank test. Efficacy data 
from ALFA-0701 study are summarised in Table 8, and the Kaplan-Meier plot for EFS is shown in Figure 1.

Table 8. Efficacy results from study ALFA-0701 (mITT population)
MYLOTARG + 

daunorubicin + cytarabine daunorubicin + cytarabine
Event-free survival (by Investigator) N=135 N=136

Number of events, n (%) 73 (54.1) 102 (75.0)
Median EFS in months [95% CI]a, 17.3 [13.4, 30.0] 9.5 [8.1, 12.0]
2-year EFS probability[95% CI]b 42.1 [32.9, 51.0] 18.2 [11.1, 26.7]
3-year EFS probability [95% CI]b 39.8 [30.2, 49.3] 13.6 [5.8, 24.8]

Hazard ratio [95% CI]c 0.562 [0.415, 0.762]
p-valued 0.0002

Relapse-free survival (by Investigator) N=110 N=100
Number of events, n (%) 49 (44.5) 66 (66.0)
Median RFS in months [95% CI]a 28.0 [16.3, NE] 11.4 [10.0, 14.4]
Hazard ratio [95% CI] c 0.526 [0.362, 0.764]
p-valued 0.0006

Overall survival N=135 N=136
Number of deaths, n (%) 80 (59.3) 88 (64.7)
Median OS in months [95% CI]a 27.5 [21.4, 45.6] 21.8 [15.5, 27.4]
Hazard ratio [95% CI]c 0.807 [0.596, 1.093]
p-valued 0.1646

Response rate (by Investigator) N=135 N=136
Overall response % [95% CI]e 81.5 [73.89, 87.64] 73.5 [65.28, 80.72]
CR 70.4 69.9
CRp 11.1 3.7
Risk difference [95% CI]f 7.95[-3.79, 19.85]
p-valueg 0.1457

Based on the primary definition of EFS: event dates (induction failure, relapse, or death) determined by investigator 
assessment. 
The mITT population included all patients who were randomised, unless withdrawal of consent prior to start of treatment 
and were analysed according to initial randomisation arm.
Abbreviations: CR=complete remission; CRp=complete remission with incomplete platelet recovery; CI=confidence 
interval; EFS=event-free survival; mITT=modified intent-to-treat; n=number; N=number; NE= not estimable; OS=overall 
survival; RFS=relapse-free survival.
a. Median estimated by Kaplan-Meier method; CI based on the Brookmeyer-Crowley method with log-log transformation.
b. Estimated from Kaplan-Meier curve. Probability (%) calculated by the product-limit method; CI calculated from the log-

log transformation of survival probability using a normal approximation and the Greenwood formula.
c. Based on the Cox proportional hazards model Versus daunorubicin + cytarabine.
d. 2-sided p-value from the log-rank test.
e. Response defined as CR+CRp.
f. Overall response difference; CI based on Santner and Snell method.
g. Based on Fisher’s exact test.



18

Figure 1. Kaplan-Meier plot of event-free survival by investigator assessment from 
study ALFA-0701 (mITT population)

Abbreviations: C=cytarabine; D=daunorubicin; GO=gemtuzumab ozogamicin; mITT=modified intent-to-treat.

Use in AML with adverse-risk cytogenetics

In subgroup analyses in ALFA-0701, the addition of MYLOTARG to standard combination chemotherapy 
did not improve EFS in the subgroup of patients having adverse-risk cytogenetics (HR 1.11; 95% CI: 0.63, 
1.95). EFS and OS analysed by cytogenetic risk classification and cytogenetic/molecular risk classification 
are presented in Table 9 and Table 10 below.



19

Table 9. Event-free survival by investigator assessment by AML risk classifications from study 
ALFA-0701 (mITT Population)

MYLOTARG + 
daunorubicin + 

cytarabine

daunorubicin +
cytarabine

Cytogenetics (favourable/intermediate), N 94 95
Number of events, n (%) 44 (46.8) 68 (71.6)
Median EFS in months [95% CI]a 22.5 [15.5, NE] 11.6 [8.3, 13.7]
Hazard ratio [95% CI]b 0.460 [0.313, 0.676]
p-valuec < 0.0001

Cytogenetics (unfavourable), N 27 30
Number of events, n (%) 23 (85.2) 26 (86.7)
Median EFS in months [95% CI]a 4.5 [1.1, 7.4] 2.8 [1.6, 8.7]
Hazard ratio [95% CI]b 1.111 [0.633, 1.949]
p-valuec 0.7151

ELN (favourable/intermediate), N 86 91
Number of events, n (%) 40 (46.5) 63 (69.2)
Median EFS in months [95% CI]a 22.5 [15.5, NE] 12.2 [8.5, 14.3]
Hazard ratio [95% CI]b 0.485 [0.325, 0.724]
p-valuec 0.0003

ELN (poor/adverse), N 37 36
Number of events, n (%) 27 (73.0) 32 (88.9)
Median EFS in months [95% CI]a 7.4 [3.7, 14.3] 4.0 [1.7, 8.6]
Hazard ratio [95% CI]b 0.720 [0.430, 1.205]
p-valuec 0.2091

The ALFA-0701 trial was not designed to prospectively evaluate the benefit of MYLOTARG in subgroups; analysis are 
presented for descriptive purposes only.
Based on the primary definition of EFS: event dates (induction failure, relapse, or death) determined by investigator 
assessment. 
The mITT population included all patients who were randomised, unless withdrawal of consent prior to start of treatment and 
were analysed according to initial randomisation arm.
Abbreviations: AML =acute myeloid leukaemia; CI=confidence interval; EFS=event-free survival; ELN=European 
LeukaemiaNet; mITT=modified intent-to-treat; n=number; N=number; NE=not estimable.
a. Median estimated by Kaplan-Meier method; CI based on the Brookmeyer and Crowley Method with log-log 

transformation.
b. Based on the Cox Proportional Hazards Model Versus daunorubicin+cytarabine.
c. 2-sided p-value from the log-rank test.



20

Table 10. Overall survival by AML risk classifications from study ALFA-0701 (mITT Population)
MYLOTARG + 
daunorubicin + 

cytarabine

daunorubicin +
cytarabine

Cytogenetics (favourable/intermediate), N 94 95
Number of deaths, n (%) 51 (54.3) 57 (60.0)
Median OS in months [95% CI]a 38.6 [24.4, NE] 26.0 [18.9, 39.7]
Hazard ratio [95% CI]b 0.747 [0.511, 1.091]
p-valuec 0.1288

Cytogenetics (unfavourable), N 27 30
Number of deaths, n (%) 24 (88.9) 24 (80.0)
Median OS in months [95% CI]a 12.0 [4.2, 14.2] 13.5 [9.4, 27.3]
Hazard ratio [95% CI]b 1.553 [0.878, 2.748]
p-valuec 0.1267

ELN (favourable/intermediate), N 86 91
Number of deaths, n (%) 44 (51.2) 53 (58.2)
Median OS in months [95% CI]a 45.6 [25.5, NE] 26.9 [19.3, 46.5]
Hazard ratio [95% CI]b 0.730 [0.489, 1.089]
p-valuec 0.1216

ELN (poor/adverse), N 37 36
Number of deaths, n (%) 31 (83.8) 29 (80.6)
Median OS in months [95% CI]a 13.2 [7.0, 18.5] 13.5 [10.8, 19.8]
Hazard ratio [95% CI]b 1.124 [0.677, 1.867]
p-valuec 0.6487

The ALFA-0701 trial was not designed to prospectively evaluate the benefit of MYLOTARG in subgroups; analysis are 
presented for descriptive purposes only.
The mITT population included all patients who were randomised, unless withdrawal of consent prior to start of treatment and 
were analysed according to initial randomisation arm.
Abbreviations: AML=acute myeloid leukaemia; CI=confidence interval; ELN=European LeukaemiaNet; mITT=modified 
intent-to-treat; n=number; N=number; NE=not estimable; OS=Overall Survival
a. Median estimated by Kaplan-Meier method; CI based on the Brookmeyer and Crowley Method with log-log 

transformation.
b. Based on the Cox Proportional Hazards Model Versus daunorubicin + cytarabine.
c. 2-sided p-value from the log-rank test.

Paediatric population

Previously untreated AML

In a randomised study (COG AAML0531) that evaluated standard chemotherapy alone or combined with 
MYLOTARG in 1,063 newly diagnosed children with AML (93.7% of patients < 18 years of age), and 
young adults (6.3% of patients); mean age was 8.9 years (range: 0-29 years), patients with de novo AML 
were randomly assigned to either standard 5-course chemotherapy alone or to the same chemotherapy with 
2 doses of MYLOTARG (3 mg/m2/dose) administered once in induction Course 1 and once in intensification 
Course 2. The study showed that addition of MYLOTARG to intensive chemotherapy improved EFS 
(3 years: 50.6% versus 44.0%; HR 0.838; 95% CI: 0.706, 0.995; p=0.0431) in de novo AML owing to a 
reduced relapse risk, with a trend towards longer OS in the MYLOTARG arm which was not statistically 
significant (3 years: 72.4% versus 67.6%; HR 0.904; 95% CI: 0.721, 1.133; p=0.3799). However, it was also 
found that increased toxicity (post-remission toxic mortality) was observed in patients with low-risk AML 
which was attributed to the prolonged neutropenia that occurred after receiving gemtuzumab ozogamicin
during intensification Course 2 (see sections 4.2 and 4.8). Overall, 29 (5.5%) of patients in the MYLOTARG 
arm and 15 (2.8%) patients in the comparator arm died during remission. Thus, the optimal dose of 
gemtuzumab ozogamicin for paediatric patients was not established (see section 4.2).

Relapsed or refractory AML

A systematic literature review of studies was conducted to evaluate MYLOTARG in paediatric patients with 
relapsed or refractory AML, which included 454 patients receiving MYLOTARG either as a monotherapy 



21

(single or fractionated dosing) or combination therapy from 16 published papers plus the US Expanded 
Access Study (see section 4.8). The median study size was 15 patients, with a range of 5-105 patients. The
overall minimum and maximum ages range from 0 years to 22.3 years, with an overall median age of
8.7 years at the time of treatment.

Most studies were in the compassionate use setting (70.6%). MYLOTARG was given as monotherapy in 
47.1%, part of a combination in 23.5%, and in both settings in 29.4% of the studies. Total dosing of 
MYLOTARG ranged from 1.8 mg/m2 to 9 mg/m2. When MYLOTARG was given in combination, a 
cytarabine based regimen was used in 8 of the 9 studies. In 23.5% of the studies the majority of patients 
received fractionated (3 mg/m2 on Day 1, 4, 7) doses of MYLOTARG, while in 35.3% of the studies doses 
higher than 3 mg/m2 were given. MYLOTARG was given as induction treatment in most studies (82.4%).

With MYLOTARG monotherapy, the response rate (CR/CRp/CRi; weighted average across studies) was
33.3% with fractionated dosing (1 study) and 24.3% with non-fractionated dosing (9 studies). In the 
combination setting, the response rate was 49.0% with non-fractionated MYLOTARG (3 studies) and 38.8% 
with fractionated MYLOTARG (2 studies). 

Safety information on myelosuppression, infections, VOD overall and VOD post-HSCT, and death, which 
are known adverse events for MYLOTARG (see section 4.8 and Table 7), was obtained from literature. 

Limitations of this analysis include the small sample size of some studies, heterogeneity of the studies, and 
the lack of control data in this setting.

5.2 Pharmacokinetic properties

Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of CD33-directed monoclonal 
antibody (hP67.6) that is covalently linked to the cytotoxic agent N-acetyl-gamma calicheamicin. The 
pharmacokinetics (PK) of gemtuzumab ozogamicin is described by measuring PK characteristics of the 
antibody (hP67.6) as well as total and unconjugated calicheamicin derivatives. Given that the hP67.6 portion 
renders target selectivity on the intact molecule, and that gemtuzumab ozogamicin dosages are reported in 
terms of milligrams of protein (hP67.6), the hP67.6 concentration results are reported as the primary PK 
measures. After gemtuzumab ozogamicin binds to the target it is internalised and N-acetyl calicheamicin is 
released by hydrolytic cleavage. Determination of PK parameters for unconjugated calicheamicin was 
limited due to the low systemic concentration levels.

No clinical PK data have been collected using the fractionated regimen; however, the PK have been 
simulated using the population PK model. Although the total dose of the fractionated dosing regimen is half 
of that of the original dosing regimen (9 versus 18 mg/m2), the predicted total AUC of hP67.6 over the 
course of treatment is 25%, and Cmax is 24%, of the values for original 9 mg/m2 dosing regimen, since the PK 
is nonlinear. When gemtuzumab ozogamicin is administered at 3 mg/m2 on Days 1, 4, and 7, the Cmax of 
hP67.6, which would occur at the end of infusion, is predicted to be 0.38 mg/L following the first dose and 
increased to 0.63 mg/L after the third dose.

Distribution

In vitro, the binding N-acetyl gamma calicheamicin dimethyl hydrazide to human plasma proteins is 
approximately 97%. In vitro, N-acetyl gamma calicheamicin dimethyl hydrazide is a substrate of 
P-glycoprotein (P-gp). In patients, the total volume of distribution of hP67.6 antibody (sum of V1 [10 L] and 
V2 [15 L]) was found to be approximately 25 L. 

Biotransformation

The primary metabolic pathway of gemtuzumab ozogamicin is anticipated to be hydrolytic release of 
N acetyl gamma calicheamicin dimethyl hydrazide. In vitro studies demonstrated that 
N-acetyl gamma calicheamicin dimethyl hydrazide is extensively metabolised, primarily via nonenzymatic 
reduction of the disulphide moiety. The activity (cytotoxicity) of the resultant metabolites is expected to be 



22

significantly attenuated. In patients, unconjugated calicheamicin plasma levels were typically low, with a
predicted mean Cmax of 1.5 ng/mL following the third dose.

Interactions with other medicinal products

Effect of other medicinal products on gemtuzumab ozogamicin

In vitro, N-acetyl gamma calicheamicin dimethyl hydrazide is primarily metabolised via nonenzymatic 
reduction. Therefore, coadministration of gemtuzumab ozogamicin with inhibitors or inducers of cytochrome 
P450 (CYP) or uridine diphosphate glucuronosyltransferase (UGT) drug metabolising enzymes are unlikely 
to alter exposure to N-acetyl gamma calicheamicin dimethyl hydrazide.

Based on population pharmacokinetic (PK) analyses, the combination of gemtuzumab ozogamicin with 
hydroxyurea, DNR, and AraC is not predicted to cause clinically meaningful changes in the PK of hP67.6 or 
unconjugated calicheamicin.

Effect of gemtuzumab ozogamicin on other medicinal products

Effect on CYP substrates

In vitro, N-acetyl gamma calicheamicin dimethyl hydrazide and gemtuzumab ozogamicin had a low 
potential to inhibit the activities of CYP1A2, CYP2A6 (tested only using gemtuzumab ozogamicin),
CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5 at clinically relevant concentrations. In 
vitro, N-acetyl gamma calicheamicin dimethyl hydrazide and gemtuzumab ozogamicin had a low potential to 
induce the activities of CYP1A2, CYP2B6, and CYP3A4 at clinically relevant concentrations.

Effect on UGT substrates

In vitro, N-acetyl gamma calicheamicin dimethyl hydrazide had a low potential to inhibit the activities of 
UGT1A1, UGT1A4, UGT1A6, UGT1A9, and UGT2B7 at clinically relevant concentrations.

Effect on drug transporter substrates

In vitro, N-acetyl gamma calicheamicin dimethyl hydrazide had a low potential to inhibit the activities of 
P-gp, breast cancer resistance protein (BCRP), bile salt export pump (BSEP), multidrug resistance associated 
protein (MRP) 2, multidrug and toxin extrusion protein (MATE)1 and MATE2K, organic anion transporter 
(OAT)1 and OAT3, organic cation transporter (OCT)1 and OCT2, and organic anion transporting 
polypeptide (OATP)1B1 and OATP1B3 at clinically relevant concentrations.

Effect on co-administered chemotherapeutic agents

Based on population pharmacokinetic (PK) analyses, the combination of gemtuzumab ozogamicin with DNR 
and AraC is not predicted to cause clinically meaningful changes in the PK of these agents.

Elimination

Based on Population PK analyses, the predicted clearance (CL) value of hP67.6 from plasma was 3 L/h 
immediately after the first dose and then 0.3 L/h. The terminal plasma half-life (t½) for hP67.6 was predicted 
to be approximately 160 hours for a typical patient at the recommended dose level (3 mg/m2) of 
MYLOTARG. 

Pharmacokinetics in specific groups of subjects or patients

Age, race, and gender

Based on a population PK analysis, age, race, and gender did not significantly affect gemtuzumab 
ozogamicin disposition.



23

Hepatic impairment

No formal PK studies of gemtuzumab ozogamicin have been conducted in patients with hepatic impairment. 

Based on a population PK analysis, the clearance of gemtuzumab ozogamicin (hP67.6 antibody and 
unconjugated calicheamicin) is not expected to be affected by mild hepatic impairment status, as defined by 
National Cancer Institute Organ Dysfunction Working Group (NCI ODWG). The analysis included 
405 patients in the following NCI ODWG impairment status categories: mild (B1, n=58 and B2, n=19), 
moderate (C, n=6), and normal hepatic function (n=322) (see section 4.2).

Renal impairment

No formal PK studies of gemtuzumab ozogamicin have been conducted in patients with renal impairment. 

Based on a population PK analysis in 406 patients, the clearance of gemtuzumab ozogamicin in patients with 
mild renal impairment (creatinine clearance [CLcr] 60-89 mL/min; n=149) or moderate renal impairment 
(CLcr 30-59 mL/min; n=47), was similar to patients with normal renal function (CLcr ≥ 90 mL/min; n=209). 
The PK of gemtuzumab ozogamicin has not been studied in patients with severe renal impairment.

Paediatric population

The results of the population modelling showed that the PK behaviour of gemtuzumab ozogamicin (hP67.6 
antibody and unconjugated calicheamicin) is similar between adult and paediatric AML patients following 
the 9 mg/m2 dosing regimen.

5.3 Preclinical safety data

Repeat-dose toxicity

The main toxicities occurred in the liver, bone marrow and lymphoid organs, haematology parameters 
(decreased RBC mass and WBC counts, mainly lymphocytes), kidney, eye and male and female reproductive 
organs. Effects on liver, kidney and male reproductive organs in rats, and on lymphoid tissues in monkeys 
(approximately 18 times for rats, and 36 times for monkeys, the human clinical exposure after the third 
human dose of 3 mg/m2 based on AUC168) were not reversible. Effects on female reproductive organs and 
the eye in monkeys were adverse in the 12-week study (approximately 193 and 322 times, respectively, the 
human clinical exposure after the third human dose of 3 mg/m2 based on AUC168). The relevance of the 
irreversible animal findings to humans is uncertain. Nervous system effects have not been observed in 
animals after administration of MYLOTARG. Nervous system alterations were identified in rats with other 
antibody-calicheamicin conjugates.

Genotoxicity

Gemtuzumab ozogamicin was found to be clastogenic. This is consistent with the known induction of DNA 
breaks by calicheamicin and other enediyne antitumour antibiotics. N-acetyl gamma calicheamicin DMH 
(the released cytotoxin) was found to be mutagenic and clastogenic.

Carcinogenicity

Formal carcinogenicity studies have not been conducted with gemtuzumab ozogamicin. In toxicity studies, 
rats developed preneoplastic lesions (minimal to slight oval cell hyperplasia) in the liver approximately 
54 times the human clinical exposure after the third human dose of 3 mg/m2 based on AUC168. There were no 
preneoplastic or neoplastic lesions observed in monkeys up to approximately 115 times the human clinical 
exposure after the third human dose of 3 mg/m2 based on AUC168. The relevance of these animal findings to 
humans is uncertain.



24

Reproductive toxicity

In a female rat fertility study slightly lower numbers of corpora lutea and increased embryolethality were 
observed in the presence of maternal toxicity (approximately 9.7 times the human clinical exposure after the 
third human dose of 3 mg/m2 based on AUC168). Effects on the reproductive tract of female monkeys were 
observed in the 12-week study (atrophy of the ovary, oviduct, uterus, and cervix; approximately 193 times 
the human clinical exposure after the third dose of 3 mg/m2). 

In a male fertility study, effects on male reproduction included lower spermatogonia and spermatocytes, 
decreases in testicular spermatids and epididymal sperm, vacuolation of the nucleus in spermatids, and/or 
appearance of giant cells. Additional findings included effects on the testes, epididymides and mammary 
gland as well as fertility. When male rats were mated again after a 9-week non-dosing period, effects on 
sperm and fertility were worse but there was partial recovery of the lower spermatogonia and spermatocytes 
in the testes. Effects on male rat reproductive organs were partially reversible or not reversible (see 
section 4.6). Male reproductive effects (testes, epididymides, seminal vesicles) in monkeys were observed at 
approximately 66 times the human clinical exposure after the third dose of 3 mg/m2.

In an embryo-foetal toxicity study lower foetal body weight, higher incidence of foetal wavy ribs, and lower 
incidence of foetal skeletal ossification were observed. Increased embryolethality and foetal morphological 
anomalies included digital malformations, absence of the aortic arch, anomalies in the long bones in the 
forelimbs, misshapen scapula, absence of a vertebral centrum, and fused sternebrae. Increased 
embryolethality was also observed in the presence of maternal toxicity. The lowest dose with embryo-foetal
effects correlated with 9.7 times the human clinical exposure after the third human dose of 3 mg/m2, based 
on AUC168 (see section 4.6).

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Dextran 40
Sucrose
Sodium chloride
Sodium dihydrogen phosphate monohydrate
Disodium hydrogen phosphate anhydrous

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal 
products.

6.3 Shelf life

Unopened vial

5 years

Reconstituted and diluted solution

Protect the reconstituted and diluted MYLOTARG solutions from light. The solutions should be used 
immediately. Do not freeze the reconstituted or diluted solution. 



25

If the product cannot be used immediately:
 Following reconstitution, the original vial may be stored up to 16 hours in a refrigerator (2°C–8°C) 

or up to 3 hours at room temperature (below 30°C).
 The diluted solution may be stored up to 18 hours in a refrigerator (2°C–8°C) and up to 6 hours at 

room temperature (below 30°C). The allowed time at room temperature (below 30°C) includes the 
time required for preparation of the diluted solution, equilibration, if needed, and administration to 
the patient. The maximum time from preparation of the diluted solution through administration 
should not exceed 24 hours.

6.4 Special precautions for storage

Store in a refrigerator (2C-8°C).
Do not freeze.
Store the vial in the original carton to protect from light.

For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.

6.5 Nature and contents of container

Amber Type 1 glass vial, with butyl rubber stopper and crimp seal with flip-off cap containing 5 mg 
gemtuzumab ozogamicin. 
Each carton contains 1 vial.

6.6 Special precautions for disposal and other handling

Use appropriate aseptic technique for the reconstitution and dilution procedures. MYLOTARG is light 
sensitive and should be protected from ultraviolet light during reconstitution, dilution, and administration.

Reconstitution

 Calculate the dose (mg) of MYLOTARG required.
 Prior to reconstitution, allow the vial to reach room temperature (below 30°C) for approximately 

5 minutes. Reconstitute each 5 mg vial with 5 mL of water for injections to obtain a single-use solution 
of 1 mg/mL of gemtuzumab ozogamicin.

 Gently swirl the vial to aid dissolution. Do not shake.
 Inspect the reconstituted solution for particulates and discolouration. The reconstituted solution may 

contain small white to off-white, opaque to translucent, and amorphous to fibre-like particles. 
 MYLOTARG contains no bacteriostatic preservatives. 
 If the reconstituted solution cannot be used immediately, it may be stored in the original vial for up to 

16 hours in a refrigerator (2°C–8°C) or up to 3 hours at room temperature (below 30°C). Protect from 
light and do not freeze.

Dilution

 Calculate the required volume of the reconstituted solution needed to obtain the appropriate dose 
according to patient body surface area. Withdraw this amount from the vial using a syringe. Mylotarg 
vials contain 5 mg of drug product with no overfill. When reconstituted to a 1 mg/mL concentration as 
directed, the extractable content of the vial is 4.5 mg (4.5 mL). Protect from light. Discard any unused 
reconstituted solution left in the vial.

 Doses must be mixed to a concentration between 0.075 mg/mL to 0.234 mg/mL according to the 
following instructions:

o Doses less than 3.9 mg must be prepared for administration by syringe. Add the reconstituted 
MYLOTARG solution to a syringe with sodium chloride 9 mg/mL (0.9%) solution for injection 
to a final concentration between 0.075 mg/mL to 0.234 mg/mL. Protect from light.



26

o Doses greater than or equal to 3.9 mg are to be diluted in a syringe or an IV bag in an 
appropriate volume of sodium chloride 9 mg/mL (0.9%) solution for injection to ensure a final 
concentration between 0.075 mg/mL to 0.234 mg/mL. Protect from light.

 Gently invert the infusion container to mix the diluted solution. Do not shake.
 Following dilution with sodium chloride 9 mg/mL (0.9%) solution for injection, MYLOTARG solution 

should be infused immediately. If not used immediately, the diluted solution may be stored up to 
18 hours in a refrigerator (2°C–8°C) and up to 6 hours at room temperature (below 30°C). The allowed 
time at room temperature (below 30°C) includes the time required for preparation of the diluted solution, 
equilibration, if needed, and administration to the patient. The maximum time from preparation of the 
diluted solution through administration should not exceed 24 hours. Protect from light and do not freeze.

 It is recommended that the infusion container be made of polyvinyl chloride (PVC) with DEHP, ethylene 
vinyl acetate (EVA) or polyolefin (polypropylene and/or polyethylene).

Administration

 Filtration of the diluted solution is required. An in-line, low protein-binding 0.2 micron 
polyethersulphone (PES) filter must be used for infusion of MYLOTARG.

 Doses administered by syringe must utilize small bore infusion lines (microbore) with an in-line, low 
protein-binding 0.2 micron polyethersulphone (PES) filter.

 During the infusion, the intravenous bag or syringes needs to be protected from light using a light 
(including ultraviolet light) blocking cover. The infusion line does not need to be protected from light.

 Infuse the diluted solution for 2 hours. The infusion must be completed prior to the end of the allowed 
6-hour storage of the diluted solution at room temperature (below 30°C).

 Infusion lines made of PVC (DEHP- or non DEHP-containing), polyurethane or polyethylene are 
recommended.

Do not mix MYLOTARG with, or administer as an infusion with, other medicinal products.

See also section 6.3 for dilution, storage, and infusion information.

Disposal

Toxic waste disposal procedures prescribed for anticancer medicinal products must be used.

7. MARKETING AUTHORISATION HOLDER

Pfizer Europe MA EEIG
Boulevard de la Plaine 17
1050 Bruxelles
Belgium

8. MARKETING AUTHORISATION NUMBER(S) 

EU/1/18/1277/001

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 19 April 2018

10. DATE OF REVISION OF THE TEXT



27

Detailed information on this medicinal product is available on the website of the European Medicines 
Agency http://www.ema.europa.eu.



28

ANNEX II

A. MANUFACTURER OF THE BIOLOGICAL ACTIVE
SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR 
BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND 
USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE 
MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE 
SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT



29

A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND
MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer of the biological active substance

Wyeth Pharmaceutical Division of Wyeth Holdings LLC,
401 North Middletown Road,
Pearl River, New York 10965
United States

Name and address of the manufacturer responsible for batch release

Pfizer Service Company BVBA
Hoge Wei 10
B-1930, Zaventem
Belgium

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product 
Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION 

 Periodic safety update reports (PSURs)

The requirements for submission of PSURs for this medicinal product are set out in the list of Union 
reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any 
subsequent updates published on the European medicines web-portal.

The marketing authorisation holder (MAH) shall submit the first PSUR for this product within 6 months 
following authorisation.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE 
USE OF THE MEDICINAL PRODUCT

 Risk management plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and 
interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and 
any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

 At the request of the European Medicines Agency;

 Whenever the risk management system is modified, especially as the result of new information 
being received that may lead to a significant change to the benefit/risk profile or as the result of an 
important (pharmacovigilance or risk minimisation) milestone being reached. 



30

ANNEX III

LABELLING AND PACKAGE LEAFLET



31

A. LABELLING



32

PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON

1. NAME OF THE MEDICINAL PRODUCT

MYLOTARG 5 mg powder for concentrate for solution for infusion
gemtuzumab ozogamicin

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each vial contains 5 mg of gemtuzumab ozogamicin.
After reconstitution each vial contains 1 mg/mL gemtuzumab ozogamicin.

3. LIST OF EXCIPIENTS

Dextran 40, sucrose, sodium chloride, sodium dihydrogen phosphate monohydrate, disodium hydrogen 
phosphate anhydrous.

4. PHARMACEUTICAL FORM AND CONTENTS

Powder for concentrate for solution for infusion
1 vial

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Intravenous use after reconstitution and dilution.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF 
THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator.
Do not freeze.
Store in the original carton to protect from light.



33

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR 
WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 
APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Pfizer Europe MA EEIG
Boulevard de la Plaine 17
1050 Bruxelles
Belgium

12. MARKETING AUTHORISATION NUMBER(S) 

EU/1/18/1277/001

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Justification for not including Braille accepted.

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC 
SN
NN



34

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

VIAL LABEL

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

MYLOTARG 5 mg powder for concentrate
gemtuzumab ozogamicin
For IV infusion after reconstitution and dilution

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

5 mg

6. OTHER



35

B. PACKAGE LEAFLET



36

PACKAGE LEAFLET: INFORMATION FOR THE USER

MYLOTARG 5 mg powder for concentrate for solution for infusion
gemtuzumab ozogamicin

This medicine is subject to additional monitoring. This will allow quick identification of new safety 
information. You can help by reporting any side effects you may get. See the end of section 4 for how to 
report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important 
information for you.

- Keep this leaflet. You may need to read it again. 
- If you have any further questions, ask your doctor or nurse.
- If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not 

listed in this leaflet. See section 4.

What is in this leaflet

1. What MYLOTARG is and what it is used for
2. What you need to know before you are given MYLOTARG
3. How MYLOTARG will be given
4. Possible side effects
5. How to store MYLOTARG
6. Contents of the pack and other information

1. What MYLOTARG is and what it is used for

MYLOTARG contains the active substance gemtuzumab ozogamicin, an anticancer medicine, which is 
made up of a monoclonal antibody linked to a substance intended to kill cancer cells. This substance is 
delivered to cancer cells by the monoclonal antibody. A monoclonal antibody is a protein which recognises 
certain cancer cells. 

MYLOTARG is used to treat a certain type of cancer called acute myeloid leukaemia (AML) in which the 
bone marrow makes abnormal white blood cells. MYLOTARG is intended for the treatment of AML for 
patients age 15 years and above who have not tried other treatments. MYLOTARG is not for use in patients 
with a type of cancer called acute promyelocytic leukaemia (APL).

2. What you need to know before you are given MYLOTARG

MYLOTARG should not be given if you:
 are allergic to gemtuzumab ozogamicin or any of the other ingredients of this medicine (listed in 

section 6).

Warnings and precautions 
When you first receive this medicine and during the course of treatment, tell your doctor or nurse if you:

 have or ever had liver problems: MYLOTARG may cause, during or after treatment, a potentially 
life-threatening condition called hepatic venoocclusive disease, in which the blood vessels in the liver
become damaged and obstructed by blood clots which may include fluid retention, rapid weight gain, 
increased liver size (which may be painful), and ascites (excessive accumulation of fluid in the 
abdominal cavity).  

 allergic reaction: experience a high-pitched whistling sound during breathing (wheezing), difficult 
breathing, shortness of breath or cough with or without mucous, hives, itching, swelling, or feeling 
fever and chills (signs of an infusion related reaction) during or shortly after the MYLOTARG 
infusion.



37

 infection: have or think you have, an infection, develop chills or shivering, or feel warm, or have 
fever. Some infections may be serious and may be life-threatening.

 bleeding: have unusual bleeding, bleeding from your gums, bruising easily or getting nose bleeds on a 
regular basis.

 anaemia: have headaches, feel tired, experience dizziness, or look pale .
 infusion reaction: experience during or shortly after MYLOTARG infusion symptoms such as

dizziness, decreased urination, confusion, vomiting, nausea, swelling, shortness of breath, or heart 
rhythm disturbances (this may be a potentially life-threatening complication known as tumour lysis 
syndrome). 

Children and adolescents
MYLOTARG must not to be used in children and adolescents under 15 years of age because limited data are 
available in this population.

Other medicines and MYLOTARG
Tell your doctor or nurse if you are taking, have recently taken, or might take any other medicines. This 
includes medicines obtained without a prescription and herbal medicines. 

Pregnancy, breast-feeding and fertility
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your 
doctor or pharmacist for advice before you are given this medicine.

You must avoid becoming pregnant or fathering a child. Women must use 2 methods of effective 
contraception during treatment and for at least 7 months after the last dose of treatment. Men must use
2 methods of effective contraception during treatment and for at least 4 months after the last dose of 
treatment. Contact your doctor immediately if you or your partner becomes pregnant while taking this 
medicine. 

Seek advice regarding fertility preservation before treatment.

If you need treatment with MYLOTARG, you must stop breast-feeding during treatment and for at least 
1 month after treatment. Talk to your doctor.

Driving and using machines
If you feel unusually tired, dizzy or have a headache (these are very common side effects of MYLOTARG)
you should not drive or use machines.

MYLOTARG contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per dose. It is essentially ‘sodium-free’.

3. How MYLOTARG will be given

 A doctor or nurse will give you MYLOTARG through a drip in your vein (intravenous infusion [IV]) 
gradually over 2 hours.

 Your doctor or nurse will decide on the correct dose.

 Your doctor may change your dose, interrupt, or completely stop treatment with MYLOTARG if you 

have certain side effects.

 Your doctor may lower your dose based on your response to treatment.

 Your doctor will do blood tests during the treatment to check for side effects and for response to 

treatment.
 Before you receive MYLOTARG, you will be given some medicines to help reduce symptoms such as 

fever and chills, known as infusion reactions, during or shortly after the MYLOTARG infusion.

If you have any further questions on the use of this medicine, ask your doctor or nurse.



38

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Some of the side effects could be serious and may occur during or after treatment with MYLOTARG. 
Immediately contact your doctor if you experience any of the following serious side effects (see also section 
2 “What you need to know before you are given MYLOTARG”):

 Liver problems
Tell your doctor right away if you have rapid weight gain, feel pain in the upper right side of your 
abdomen, have accumulation of fluid causing abdominal swelling. Your doctor may do blood tests 
and find abnormalities in liver blood tests, which might be signs of a potentially life-threatening 
condition called venoocclusive liver disease.

 Bleeding (signs of a low number of blood cells known as platelets)
Tell your doctor right away if you bruise easily or get nose bleeds on a regular basis, or have black 
tarry stools, coughing up of blood, bloody sputum, or change in your mental status.

 Infections (signs of a low number of white blood cells known as neutrophils)
Some infections may be serious and can be due to viruses, bacteria, or other causes that may be 
life-threatening.

 Complication known as tumour lysis syndrome
Tell your doctor right away if you experience dizziness, decreased urination, confusion, vomiting, 
nausea, swelling, shortness of breath, or heart rhythm disturbances.

 Infusion reactions
Medicines of this type (monoclonal antibodies) can cause infusion reactions such as a rash, shortness 
of breath, difficulty breathing, a tight chest, chills or fever, back pain. 

Other side effects may include:

Very common (may affect more than 1 in 10 people):
 Infections (including serious infections)
 Reduced number of blood platelets (cells that help blood to clot)
 Reduced number of white blood cells which may result in general weakness and a tendency to 

develop infections
 Reduced number of red blood cells (anaemia) which may result in fatigue and shortness of breath
 High blood sugar
 Decreased appetite
 Headache
 Rapid heartbeat
 Bleeding
 Low blood pressure
 High blood pressure
 Shortness of breath
 Vomiting
 Diarrhoea
 Pain in the abdomen
 Feeling sick (nausea)
 Mouth inflammation
 Constipation
 Abnormalities in liver blood tests (which can be indicators of liver injury)
 Skin rash
 Fever



39

 Oedema (excess fluid in body tissue, causing swelling of the hands and feet)

 Fatigue
 Chills
 Changes in the levels of different enzymes in the blood (may show in your blood tests)
 Prolonged clotting time
 High level of uric acid in the blood

Common (may affect up to 1 in 10 people):
 Signs of an infusion reaction, such as a rash, shortness of breath, difficulty breathing, a tight chest,

chills or fever, back pain during or after MYLOTARG infusion
 Signs of an enlarged liver (hepatomegaly), such as an enlarged belly
 Abnormal liver function
 Excessive accumulation of fluid in the abdomen/stomach
 Indigestion
 Inflammation of the oesophagus (swallowing tube)
 Liver venoocclusive disease (VOD), which includes signs of enlarged liver, pain in the upper right

belly, yellowing of the skin and the whites of the eyes, accumulation of fluid in the abdomen, weight
gain, abnormal liver blood tests

 Yellowing of the skin or whites of the eyes caused by liver or blood problems (jaundice)
 Redness of the skin
 Itchy skin
 Organ failure

Uncommon (may affect up to 1 in 100 people):
 Liver failure
 Budd-Chiari syndrome, which includes pain in the upper right part of the belly, an abnormally large

liver, and/or accumulation of fluid in the belly associated with blood clots in the liver. Symptoms
may also include feeling sick (nausea) and/or vomiting.

Frequency unknown (frequency cannot be estimated from the available data):
 Interstitial pneumonia (inflammation of the lungs causing coughing and difficulty breathing)
 Inflammation of the bowel in association with low white blood cell counts
 Inflammation of the urinary bladder resulting in bleeding from the bladder

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system listed in 
Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store MYLOTARG

MYLOTARG will be stored by the health professionals at the hospital or clinic.

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the vial label and carton after EXP. The 
expiry date refers to the last day of that month.

Unopened vial: Store in a refrigerator (2°C–8°C). Do not freeze. Store the vial in the original carton to 
protect from light. 

Reconstituted and diluted solution: Protect the reconstituted and diluted MYLOTARG solutions from 
light. The solutions should be used immediately. Do not freeze the reconstituted or diluted solution. 



40

If not used immediately:

 Following reconstitution, the original vial may be stored up to 16 hours in a refrigerator (2°C–8°C) 
or up to 3 hours at room temperature (below 30°C).

 The diluted solution may be stored up to 18 hours in a refrigerator (2°C–8°C) and up to 6 hours at 
room temperature (below 30°C). The allowed time at room temperature (below 30°C) includes the 
time required for preparation of the diluted solution, equilibration, if needed, and administration. The 
maximum time from preparation of the diluted solution through administration should not exceed 24 
hours.

Do not use this medicine if you notice any particulate matter or discolouration prior to administration.

Do not throw away any medicines via wastewater or household waste. Ask your doctor how to throw away 
medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What MYLOTARG contains 
 The active substance is gemtuzumab ozogamicin. 
 Each vial contains 5 mg gemtuzumab ozogamicin.
 After reconstitution, each ml of the concentrated solution contains 1 mg gemtuzumab ozogamicin.
 The other ingredients are dextran 40, sucrose, sodium chloride, sodium dihydrogen phosphate 

monohydrate, disodium hydrogen phosphate anhydrous. See section 2, “MYLOTARG contains 
sodium”.

What MYLOTARG looks like and contents of the pack

MYLOTARG is a powder for concentrate for solution for infusion. It is supplied as white to off-white cake 
or powder.

Each carton contains 1 amber, glass vial, with rubber stopper and crimp seal with flip-off cap.

Marketing Authorisation Holder 

Pfizer Europe MA EEIG
Boulevard de la Plaine 17
1050 Bruxelles
Belgium

Manufacturer

Pfizer Service Company BVBA
Hoge Wei 10
B-1930, Zaventem
Belgium



41

For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder:

Belgique/België /Belgien
Pfizer S.A. / N.V.
Tél/Tel: +32 (0)2 554 62 11

Lietuva
Pfizer Luxembourg SARL filialas Lietuvoje
Tel: + 370 52 51 4000

България
Пфайзер Люксембург САРЛ, Клон 
България
Тел.: +359 2 970 4333

Luxembourg/Luxemburg
Pfizer S.A.
Tél/Tel: +32 (0)2 554 62 11

Česká republika
Pfizer, spol. s r.o.
Tel: +420 283 004 111

Magyarország
Pfizer Kft.
Tel: +36-1-488-37-00

Danmark
Pfizer ApS
Tlf: +45 44 20 11 00

Malta
Vivian Corporation Ltd.
Tel: + 35621 344610

Deutschland
Pfizer Pharma GmbH
Tel: +49 (0)30 550055 51000

Nederland
Pfizer bv
Tel: +31 (0)10 406 43 01

Eesti
Pfizer Luxembourg SARL Eesti filiaal
Tel: +372 666 7500

Norge
Pfizer AS
Tlf: +47 67 52 61 00

Ελλάδα
Pfizer Ελλάς A.E.
Τηλ: +30 210 6785 800

Österreich
Pfizer Corporation Austria Ges.m.b.H.
Tel: +43 (0)1 521 15-0

España
Pfizer, S.L.
Tel: +34 91 490 99 00

Polska
Pfizer Polska Sp. z o.o.
Tel: +48 22 335 61 00

France
Pfizer
Tel: +33 (0)1 58 07 34 40

Portugal
Laboratórios Pfizer, Lda.
Tel: +351 21 423 5500

Hrvatska
Pfizer Croatia d.o.o.
Tel: + 385 1 3908 777

România
Pfizer Romania S.R.L.
Tel: +40 (0) 21 207 28 00

Ireland
Pfizer Healthcare Ireland
Tel: 1800 633 363 (toll free)
+44 (0)1304 616161

Slovenija
Pfizer Luxembourg SARL
Pfizer, podružnica za svetovanje s področja
farmacevtske dejavnosti, Ljubljana
Tel: + 386 (0)1 52 11 400

Ísland
Icepharma hf.
Sími: +354 540 8000

Slovenská republika
Pfizer Luxembourg SARL, organizačná zložka
Tel: + 421 2 3355 5500



42

Italia
Pfizer S.r.l.
Tel: +39 06 33 18 21

Suomi/Finland
Pfizer Oy
Puh/Tel: +358 (0)9 43 00 40

Κύπρος
Pfizer Ελλάς Α.Ε. (Cyprus Branch)
Τηλ: +357 22 817690

Sverige
Pfizer AB
Tel: +46 (0)8 550-520 00

Latvija
Pfizer Luxembourg SARL filiāle Latvijā
Tel: + 371 670 35 775

United Kingdom
Pfizer Limited
Tel: +44 (0) 1304 616161

This leaflet was last revised in

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site: 

http://www.ema.europa.eu. There are also links to other websites about rare diseases and treatments.

-----------------------------------------------------------------------------------------------------------------------------
The following information is intended for healthcare professionals only:

Use appropriate aseptic technique for the reconstitution and dilution procedures. MYLOTARG is light 
sensitive and should be protected from ultraviolet light during reconstitution, dilution and administration.

Reconstitution
 Calculate the dose (mg) of MYLOTARG required.
 Prior to reconstitution, allow the vial to reach room temperature (below 30°C) for approximately

5 minutes. Reconstitute each 5 mg vial with 5 mL of water for injections to obtain a single-use
solution of 1 mg/mL of gemtuzumab ozogamicin.

 Gently swirl the vial to aid dissolution. Do not shake.
 Inspect the reconstituted solution for particulates and discolouration. The reconstituted solution may

contain small white to off-white, opaque to translucent, and amorphous to fibre-like particles.
 MYLOTARG contains no bacteriostatic preservatives.
 If the reconstituted solution cannot be used immediately, it may be stored in the original vial for up to

16 hours in a refrigerator (2°C–8°C) or up to 3 hours at room temperature (below 30°C). Protect from
light and do not freeze.

Dilution
 Calculate the required volume of the reconstituted solution needed to obtain the appropriate dose

according to patient body surface area. Withdraw this amount from the vial using a syringe. Mylotarg 
vials contain 5 mg of drug product with no overfill. When reconstituted to a 1 mg/mL concentration 
as directed, the extractable content of the vial is 4.5 mg (4.5 mL). Protect from light. Discard any 
unused reconstituted solution left in the vial. 

 Doses must be mixed to a concentration between 0.075 mg/mL to 0.234 mg/mL according to the
following instructions:

o Doses less than 3.9 mg must be prepared for administration by syringe. Add the
reconstituted MYLOTARG solution to a syringe with sodium chloride 9 mg/mL (0.9%) 
solution for injection to a final concentration between 0.075 mg/mL to 0.234 mg/mL. Protect 
from light.

o Doses greater than or equal to 3.9 mg are to be diluted in a syringe or an IV bag in an
appropriate volume of sodium chloride 9 mg/mL (0.9%) solution for injection to ensure a 
final concentration between 0.075 mg/mL to 0.234 mg/mL. Protect from light.

 Gently invert the infusion container to mix the diluted solution. Do not shake.



43

 Following dilution with sodium chloride 9 mg/mL (0.9%) solution for injection, MYLOTARG 
solution should be infused immediately. If not used immediately, the diluted solution may be stored 
up to 18 hours in a refrigerator (2°C–8°C) and up to 6 hours at room temperature (below 30°C). The 
allowed time at room temperature (below 30°C) includes the time required for preparation of the 
diluted solution, equilibration, if needed, and administration to the patient. The maximum time from 
preparation of the diluted solution through administration should not exceed 24 hours. Protect from 
light and do not freeze.

 It is recommended that the infusion container be made of polyvinyl chloride (PVC) with DEHP, 
ethylene vinyl acetate (EVA) or polyolefin (polypropylene and/or polyethylene).

Administration
 Filtration of the diluted solution is required. An in-line, low protein-binding 0.2 micron 

polyethersulphone (PES) filter must be used for infusion of MYLOTARG.
 Doses administered by syringe must utilize small bore infusion lines (microbore) with an in-line, low 

protein-binding 0.2 micron polyethersulphone (PES) filter.
 During the infusion, the intravenous bag or syringes needs to be protected from light using a light

(including ultraviolet light) blocking cover. The infusion line does not need to be protected from light.
 Infuse the diluted solution for 2 hours. The infusion must be completed prior to the end of the allowed 

6-hour storage of the diluted solution at room temperature (below 30°C).
 Infusion lines made of PVC (DEHP- or non-DEHP-containing), polyurethane or polyethylene are 

recommended.

Do not mix MYLOTARG with, or administer as an infusion with, other medicinal products.

Disposal
 Toxic waste disposal procedures prescribed for anticancer medicinal products must be used.


	SUMMARY OF PRODUCT CHARACTERISTICS
	A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE ANDMANUFACTURER RESPONSIBLE FOR BATCH RELEASE
	B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
	C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
	D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVEUSE OF THE MEDICINAL PRODUCT
	A. LABELLING
	B. PACKAGE LEAFLET